Phase 1 Study of Tazemetostat, An Enhancer of Zeste Homolog-2 (EZH2) Inhibitor, In Pediatric Patients With Relapsed/Refractory Integrase Interactor 1 (INI1)-Negative Tumors

被引：0

作者：

Chi, S. ^{[1
]}

Bourdeaut, F. ^{[2
]}

Laetsch, T. ^{[3
]}

Fouladi, M. ^{[4
]}

Macy, M. ^{[5
]}

Makin, G. ^{[6
]}

Shukla, N. ^{[7
]}

Wetmore, C. ^{[8
]}

Margol, A. ^{[9
]}

Casanova, M. ^{[10
]}

Kilburn, L. ^{[11
]}

Yi, J. ^{[12
,13
]}

Hargrave, D. ^{[14
]}

Mccowage, G. ^{[15
]}

Pinto, N. ^{[16
]}

Ebb, D. ^{[17
]}

Robinson, G. ^{[18
]}

Sierra, L. ^{[19
]}

Merchant, M. ^{[19
]}

Nysom, K. ^{[20
]}

机构：

[1] Dana Farber Canc Inst, Neurooncol, Boston, MA 02115 USA

[2] Curie Inst, Care Innovat Res, Childhood Canc, Adolescents & Young Adults, Paris, France

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA

[4] Cincinnati Childrens Hosp, Canc & Blood Dis, Brain Tumor, Oncol, Cincinnati, OH USA

[5] Childrens Hosp Colorado, Canc & Blood Disorders, Expt Therapeut, Oncol, Aurora, CO USA

[6] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[7] Mem Sloan Kettering Canc Ctr, Pediat Hematol Oncol, 1275 York Ave, New York, NY 10021 USA

[8] Phoenix Childrens Hosp, Hematol & Oncol, Phoenix, AZ USA

[9] Childrens Hosp Los Angeles, Canc & Blood Dis Inst, Los Angeles, CA 90027 USA

[10] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol & Hematol, Milan, Italy

[11] Childrens Natl Hosp, Brain Tumor Inst, Ctr Canc & Blood Disorders, Expt Therapeut Program,Oncol,Neurofibromatosis In, Washington, DC USA

[12] Texas Childrens Hosp, Dev Therapeut Phase Clin 1, Leukemia Program, Canc Ctr, Houston, TX 77030 USA

[13] Texas Childrens Hosp, Dev Therapeut Phase Clin 1, Leukemia Program, Hematol Ctr, Houston, TX 77030 USA

[14] Great Ormond St Hosp Sick Children, Dept Haematol & Oncol, London, England

[15] Childrens Hosp Westmead, Canc Ctr Children, Clin Trials, Westmead, NSW, Australia

[16] Seattle Childrens Hosp, Hematol Oncol, Seattle, WA USA

[17] Massachusetts Gen Hosp, Canc Care, Pediat, Boston, MA 02114 USA

[18] St Jude Childrens Res Hosp, Dept Oncol, St Jude Grad Sch Biomed Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[19] Epizyme, Early Stage Dev, Cambridge, MA USA

[20] Rigshosp, Paediat & Adolescent Med, Copenhagen, Denmark

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0261

引用

页码：S123 / S124

页数：2

共 50 条

[41] Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
Kung, Pei-Pei
Rui, Eugene
Bergqvist, Simon
Bingham, Patrick
Braganza, John
Collins, Michael
Cui, Mei
Diehl, Wade
Dac Dinh
Fan, Connie
Fantin, Valeria R.
Gukasyan, Hovhannes J.
Hu, Wenyue
Huang, Buwen
Kephart, Susan
Krivacic, Cody
Kumpf, Robert A.
Li, Gary
Maegley, Karen A.
McAlpine, Indrawan
Nguyen, Lisa
Ninkovic, Sacha
Ornelas, Martha
Ryskin, Michael
Scales, Stephanie
Sutton, Scott
Tatlock, John
Verhelle, Dominique
Wang, Fen
Wells, Peter
Wythes, Martin
Yamazaki, Shinji
Yip, Brian
Yu, Xiu
Zehnder, Luke
Zhang, Wei-Guo
Rollins, Robert A.
Edwards, Martin
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (18) : 8306 - 8325
[42] Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial
Oppelt, Peter J.
Puram, Sidharth V.
Liu, Jingxia
Ley, Jessica C.
Adkins, Douglas
CANCERS, 2025, 17 (03)
[43] Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies
Oaknin, Ana
Banda, Kalyan
Drescher, Charles
Ribrag, Vincent
Kindler, Hedy L.
Walter, Harriet S.
Tewari, Alok
Pons-Tostivint, Elvire
Lakhani, Nehal J.
Harvey, R. Donald
Sullivan, Ryan J.
Zinzani, Pier Luigi
Martin, Antonio Gonzalez
Eberst, Lauriane
Sanchez, Luis Manso
Thakur, Anjali
Kann, Lennart
Reddy, Archana
Faulhaber, Nicola
Duska, Linda
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] Enhancer of Zeste Homolog 2 (EZH2) modulation in either embryonal or PAX3-FOXO1 alveolar rhabdomyosarcoma shows different anti-tumoral effects
Rota, R.
Carcarino, E.
De Salvo, M.
Adesso, L.
Ciarapica, R.
Marquez, V. E.
Mai, A.
Puri, P. L.
Palacios, D.
Locatelli, F.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S109 - S110
[45] A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)
Yap, Timothy A.
Winter, Jane N.
Leonard, John P.
Ribrag, Vincent
Constantinidou, Anastasia
Giulino-Roth, Lisa
Michot, Jean-Marie
Khan, Tariq A.
Horner, Thierry
Carver, Jennifer
Dumetrescu, Teodora Pene
He, Zangdong
McCabe, Michael T.
Creasy, Caretha L.
Dhar, Arindam
Carpenter, Christopher
Johnson, Peter M.
BLOOD, 2016, 128 (22)
[46] A phase 1/2 study of bay 18953444 (Elimusertib) in pediatric patients with relapsed or refractory solid tumors: Initial report of the phase 1 results of PEPN2112.
Ortiz, Michael Vincent
Bender, Julia Lynne Glade
Minard, Charles G.
Liu, Xiaowei
Denic, Kristina Z.
Reid, Joel M.
Militano, Olga
Church, Alanna J.
Kentsis, Alex
Reynolds, C. Patrick
Voss, Stephan D.
Fox, Elizabeth
Weigel, Brenda
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR PDGFRA-MUTANT PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS
Chi, Susan
Hsieh, Antony
Foley, Megan
Shi, Hongliang
Swamy, Preethi
Rodstrom, Jill
Rudoltz, Marc
NEURO-ONCOLOGY, 2021, 23 : 47 - 47
[48] AN ANALYSIS OF RELAPSE/REFRACTORY RHABDOID TUMORS FROM AN OBSERVATIONAL STUDY ON PEDIATRIC SOLID TUMORS: HISTORICAL DATA FOR EZH1/2 INHIBITOR DEVELOPMENT
Tanimura, Kazuki
Ogawa, Chitose
Kato, Miho
Takimoto, Tetsuya
Oue, Takaharu
Kumabe, Toshihiro
Hirato, Junko
Kohashi, Kennichi
Okita, Hajime
Tajiri, Tatsuro
PEDIATRIC BLOOD & CANCER, 2022, 69
[49] Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
Song, Yuqin
Jin, Zhengming
Li, Zhi-Ming
Liu, Yanyan
Li, Lanfang
He, Chuan
Su, Hang
Zhou, Hui
Li, Kunyan
Hao, Siguo
Zuo, Xuelan
Wu, Jianyuan
Li, Dengju
Wu, Meng
Sun, Xiuhua
Qi, Junyuan
Cai, Zhen
Li, Zengjun
Li, Yijing
Huang, Yanhua
Shen, Jie
Xiao, Zhenyu
Zhu, Jun
CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1248 - 1255
[50] Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors
Wedekind, Mary Frances
Akshintala, Srivandana
Widemann, Brigitte C.
Minard, Charles G.
Militano, Olga
Hall, David
Bradley, Zanette
Reid, Joel M.
Pressey, Joseph Gerald
Sharon, Elad
Fox, Elizabeth
Weigel, Brenda
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →